1. Scrip
  2. >>Business

Video: BioNTech's Marett On Sanofi Deal And Immunotherapy

 
• By Lucie Ellis-Taitt

In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies.

In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.